In The Know-April 2023

April 2023
Pdf Summary
Ed's List: In The Know - Gyn Onc Literature of Significance (April 2023)<br /><br />- GYN ONC Garage video reviews: Reviews on the association of frequent aspirin use with ovarian cancer risk and common analgesics and ovarian cancer survival.<br />- Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry: A study comparing the investments made by NIH and the pharmaceutical industry in new drug approvals.<br />- Long-Term Health Consequences After Ovarian Removal at Benign Hysterectomy: A study comparing long-term outcomes in women with and without bilateral salpingo-oophorectomy during benign hysterectomy.<br />- Noncoding translation mitigation: A study on translation in noncoding regions and the mechanisms underlying translation surveillance.<br />- Impact of obesity on chemotherapy dosing of carboplatin and survival in women with ovarian cancer: A study evaluating the impact of obesity on frontline carboplatin dosing and survival in women with ovarian cancer.<br />- Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma: A study on the activity of the estrogen receptor signal transduction pathway and its association with response to antihormonal therapy in low-grade ovarian carcinoma.<br />- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer: A study on the use of dostarlimab, an immune-checkpoint inhibitor, in the treatment of advanced or recurrent endometrial cancer.<br />- Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer: A study on the addition of pembrolizumab, an immune-checkpoint inhibitor, to chemotherapy in the treatment of advanced endometrial cancer.<br />- Next-Generation Alternative Payment Models in Oncology - Will Precision Preclude Participation?: An analysis of the Oncology Care Model and its effectiveness in improving quality and reducing costs in cancer care.<br />- [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer: A study evaluating the use of [18F]FTT PET imaging as a biomarker for response to PARP inhibitors in ovarian cancer.<br />- Older women testing positive for HPV16/18 on cervical screening and risk of high-grade cervical abnormality: A study on the risk of high-grade cervical abnormality in older women testing positive for HPV16/18 on cervical screening.<br />- Risk of nonovarian cancer in women with borderline ovarian tumors: A study on the incidence of nonovarian cancers in women with borderline ovarian tumors.<br />- Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer: A study comparing the efficacy of carboplatin and paclitaxel with or without avelumab in the treatment of advanced or recurrent endometrial cancer.<br />- Postpartum Opportunistic Salpingectomy Compared With Bilateral Tubal Ligation After Vaginal Delivery for Ovarian Cancer Risk Reduction: A cost-effectiveness analysis comparing opportunistic salpingectomy with bilateral tubal ligation for reducing ovarian cancer risk.<br />- Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer: An analysis comparing the short- and long-term treatment duration of bevacizumab in advanced ovarian cancer.<br /><br />These studies cover a range of topics in gynecologic oncology, including ovarian cancer risk reduction, treatment effectiveness, and the impact of obesity on chemotherapy dosing. The findings contribute to our understanding of the field and may have implications for clinical practice.
Keywords
ovarian cancer risk
chemotherapy dosing
obesity
endometrial cancer
PARP inhibitors
cervical screening
high-grade cervical abnormality
nonovarian cancer
borderline ovarian tumors
gynecologic oncology